Fig. 3From: A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patientsStudy treatment schedule. Prior to the start of the standard CROSS treatment, patients will receive additional 18F-HX4 scans before and after the first dose of evofosfamideBack to article page